An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)

Volume: 27, Issue: 15_suppl, Pages: 4577 - 4577
Published: May 20, 2009
Abstract
4577 Background: Brivanib is an orally available dual inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signaling. FGF pathway activation is of increasing importance in the setting of liver fibrosis and HCC. This phase II study aimed to assess the efficacy and safety of brivanib in patients (pts) with unresectable, locally advanced or metastatic HCC who had received either no prior systemic therapy (Cohort A) or...
Paper Details
Title
An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)
Published Date
May 20, 2009
Volume
27
Issue
15_suppl
Pages
4577 - 4577
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.